### 31 October 2023

## 2023/24 Invitation to Tender

The 2023/24 Invitation to Tender (2023/24 ITT) has been distributed today.

If you have already registered your e-mail address with Pharmac's tendering e-portal you can access the 2023/24 ITT in the e-portal in Current Tenders.

If you have not registered your company with the e-Portal, and you would like to participate in the 2023/24 ITT, please register at <u>https://in-tendhost.co.uk/pharmac/aspx/Home</u>.

A complete copy of the 2023/24 ITT is available on <u>our website</u>. We will not be posting out any hard copies of the 2023/24 ITT.

If you wish to submit a Tender Bid in relation to community supply and/or hospital supply, you must submit it via the Electronic Portal to Pharmac no later than **4 pm (New Zealand time) on Thursday 14 December 2023.** 

### Changes to the 2023/24 ITT product list

Please note that the product list (Schedule Two) consulted on in July 2023 has changed. Some products have been added, removed or amended either as a result of:

- clinical advice received (e.g. from the Tender Clinical Advisory Committee); and/or
- feedback received on the draft 2023/24 ITT; and/or
- a review of unresolved bids from previous tenders.

The following items have been added to the 2023/24 ITT:

Chemical Name	Line Item
Adenosine	Inj 3 mg per ml, 2 ml
Adenosine	Inj 10 mg per ml, 2 ml
Amisulpride	Tab 100 mg
Amisulpride	Tab 200 mg
Amisulpride	Tab 400 mg
Amprhotericin B	Liposomal inj 50 mg
Azithromycin	Tab 250 mg
Azithromycin	Tab 500 mg
Benzylpenicillin sodium	Inj 1.2 g
Benzylpenicillin sodium	Inj 3 g
Budesonide	Metered aqueous nasal spray, 50 mcg dose

Chemical Name	Line Item
Budesonide	Metered aqueous nasal spray, 100 mcg dose
Clindamycin	Cap 150 mg
Ertapenem	lnj 1 g
Fosfomycin (Current Access)	Power
Fosfomycin (Widened Access)	Power
Furosemide	Tab 40 mg
Levosimendan	lnj 2.5 mg per ml, 5 ml
Lomustine	Cap 10 mg
Lomustine	Cap 40 mg
Noradrenaline	Inj 0.06 mg per ml, 50 ml
Noradrenaline	lnj 0.1 mg per ml, 50 ml
Pyridostigmine bromide	Tab 60 mg

### PHARMAC TE DĂTAKA WHALODANGA

Chemical Name	Line Item
Vinorelbine	Inj 10 mg per ml, 1 ml

Chemical Name	Line Item
Vinorelbine	lnj 10 mg per ml, 5 ml

## The following items have been amended in the 2023/24 ITT:

Chemical Name	Line Item
Atropine sulphate	Inj 600 mcg
Calamine	Lotn, BP
Linezolid	Tab 600 mg
Methotrexate	Inj 2.5 mg per ml, 2 ml
Sunitinib (Current Access)	Cap 12.5 mg
Sunitinib (Current Access)	Cap 25 mg

Chemical Name	Line Item
Sunitinib (Current Access)	Cap 50 mg
Sunitinib (Widened Access)	Cap 12.5 mg
Sunitinib (Widened Access)	Cap 25 mg
Sunitinib (Widened Access)	Cap 50 mg
Valganciclovir	Tab 450 mg

## The following items that were included in consultation have been removed from the 2023/24 ITT:

Chemical Name	Line Item
Clarithromycin	Tab 250 mg
Clarithromycin	Tab 500 mg
Diltiazem hydrochloride	Cap long-acting 180 mg
Diltiazem hydrochloride	Cap long-acting 240 mg
Metformin hydrochloride	Tab immediate-release 500 mg
Metformin hydrochloride	Tab immediate-release 850 mg
Metoprolol tartrate	Tab 50 mg
Metoprolol tartrate	Tab 100 mg
Mirtazapine	Tab 30 mg
Mirtazapine	Tab 45 mg

Chemical Name	Line Item
Nadolol	Tab 40 mg
Nadolol	Tab 80 mg
Propanolol	Tab 10 mg
Propanolol	Tab 40 mg
Sacubitril with valsartan	Tab 24.3 mg with valsartan 25.7 mg
Sacubitril with valsartan	Tab 48.6 mg with valsartan 51.4 mg
Sacubitril with valsartan	Tab 97.2 mg with valsartan 102.8 mg
Sumatriptan	Tab 50 mg
Sumatriptan	Tab 100 mg

#### Additional Notes

## Appropriate pack-size and packaging type

Where possible, Pharmac has identified Tender Items where there is a specific product preference in Schedule Two of the 2023/24 ITT document. For example (highlighted in red):



Metronidazole						
lnj 5 mg per ml, 100 ml				Н		Preference for a bag presentation with space to add another antibiotic.
<u>Tab 200 mg</u>	368,077	\$48,807	\$0.1326	CH	5%	Preference for a scored, dispersible tablet.
<u>Tab 400 mg</u>	2,140,052	\$532,980	\$0.2491	CH	5%	

While Pharmac has taken all reasonable care in identifying these preferences, it makes no representation as to the accuracy of this information and accepts no liability for any errors or omissions. Suppliers should always undertake their own due diligence before submitting any tender bids.

Please note: we have historically indicated a preference for the pack size of Tender Items supplied in the community to be either a 30-day or 90-day pack. This improves dispensing efficiency and reduces wastage. We will be putting greater emphasis on packaging type and pack size in the future. There is a preference for bottle packs for tablets and capsules, where possible.

In this Tender we have identified specific packaging preferences for individual products in Schedule 2. We are aiming to expand this to a much wider range of products in future Tenders.

#### **Oncology injectables**

Te Whatu Ora hospitals are increasingly delivering chemotherapy treatment in satellite centers. These centers require compounded products to have a shelf-life greater than 24 hours. This accounts for delays in treatment transport and delivery. Therefore, Pharmac has indicated a preference for products with post-compounding stability data that is greater than 48 hours.

#### **Ophthalmology Products (BAK-free)**

Pharmac reserves its right to list a benzalkonium chloride (BAK) or preservative-free product for a restricted market. This is indicated in Schedule Two of the 2023/24 ITT. However, where a tender product is BAK-free it would have the entire market.

#### Access criteria

Pharmac is tendering for current or widened access for some products. This is indicated in Schedule Two of the 2023/24 ITT document. Links to clinical advice for these products have been included below. These detail the potential access criteria. Please note any access criteria are indicative only. Pharmac reserves the right to amend these criteria.

Chemical Name	Line Item(s)
Aprepitant	Cap 40 mg Cap 80 mg Cap 125 mg Cap 165 mg
Azacitidine	Inj 100 mg
<u>Fosfomycin</u>	Powder
Ivarbardine	Tab 5 mg Tab 7.5 mg

Chemical Name	Line Item(s)	
<u>Octreotide</u>	Inj depot 10 mg pre-filled syringe Inj depot 20 mg pre-filled syringe Inj depot 30 mg pre-filled syringe	
<u>Sunitinib</u>	Cap 12.5 mg Cap 25 mg Cap 50 mg	

# Data estimates for PCT injectable products included in the 2023/24 ITT

## Usage data for PCT injectable products

Chemical Name	Total usage (mg) <sup>1</sup>
Azacitidine – Inj 1 mg for ECP	500,000
Azacitidine – Inj 100 mg vial	304,000
Bendamustine – Inj 1 mg for ECP	278,000
Bendamustine – Inj 100 mg vial	58,000
Bendamustine – Inj 25 mg vial	6,000
Calcium folinate – Inj 1 mg for ECP	276,000
Calcium folinate – Inj 3 mg per ml, 1 ml	N/A
Calcium folinate – Inj 50 mg	294,000
Calcium folinate – Inj 100 mg	147,000
Calcium folinate – Inj 300 mg	50,000
Calcium folinate – Inj 350 mg	1,959,000
Calcium folinate – Inj 1 g	N/A
Carboplatin – Inj 1 mg for ECP	2,601,000
Carboplatin – Inj 450 mg	1,052,000
Cisplatin – Inj 1 mg for ECP	209,000
Cisplatin – Inj 100 mg	83,000
Cyclophosphamide – Inj 1 mg for ECP	6,758,000
Cyclophosphamide – Inj 1 g	109,000
Cyclophosphamide – Inj 2 g	558,000
Doxorubicin – Inj 1 mg for ECP	292,000
Doxorubicin – Inj 50 mg	25,000
Doxorubicin – Inj 200 mg	124,000
Epirubicin – Inj 1 mg for ECP	83,000
Epirubicin – Inj 50 mg	29,000
Epirubicin – Inj 200 mg	1,000
Flourouracil – Inj 1 mg for ECP	38,717,000
Fluorouracil – Inj 1 g vial	17,000
Fluorouracil – Inj 5 g vial	10,230,000

Chemical Name	Total usage (mg) <sup>1</sup>
Irinotecan hydrochloride – Inj 1 mg for ECP	1,241,000
Irinotecan hydrochloride – Inj 100 mg vial	159,000
Methotrexate – Inj 1 mg for ECP	2,010,000
Methotrexate – Inj 5 mg intrthecal syringe for ECP	6,000
Methotrexate – Inj 2.5 mg per ml, 2 ml	3,000
Methotrexate – Inj 25 mg per ml, 2 ml	20,000
Methotrexate – Inj 25 mg per ml, 20 ml	N/A
Methotrexate – Inj 100 mg per ml, 10 ml	N/A
Methotrexate – Inj 7.5 mg prefilled syringe	21,000
Methotrexate – Inj 10 mg prefilled syringe	127,000
Methotrexate – Inj 15 mg prefilled syringe	210,000
Methotrexate – Inj 20 mg prefilled syringe	534,000
Methotrexate – Inj 25 mg prefilled syringe	217,000
Methotrexate – Inj 30 mg prefilled syringe	25,000
Pemetrexed – Inj 1 mg for ECP	1,083,000
Pemetrexed – Inj 100 mg vial	N/A
Pemetrexed – Inj 500 mg vial	397,000
Vinorelbine – Inj 1 mg for ECP	35,000
Vinorelbine – Inj 10 mg per ml, 1 ml vial	N/A
Vinorelbine – Inj 10 mg per ml, 5 ml vial	19,000

<sup>1</sup>Usage rounded to the nearest 1000mg, for period between 1 July 2022 to 30 June 2023



Pharmac makes no representation as to the accuracy of this information or as to the level of sales or likely sales. While Pharmac has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information.

To be fair to all suppliers, we are unlikely to provide any further data relating to tender items while the 2023/24 ITT remains open.

#### More information

If you have any queries regarding the tender or require any assistance with the e-portal please contact the Tender Analysts (Imani Kerr and James Anderson) at <u>tender@pharmac.govt.nz</u>